Related Experiment Video
Updated: Aug 14, 2025

Monitoring Changes in Human Umbilical Vein Endothelial Cells upon Viral Infection Using Impedance-Based Real-Time Cell Analysis
Published on: May 5, 2023
SARS-CoV-2 infection and SLE: endothelial dysfunction, atherosclerosis, and thrombosis
Wojciech Płazak1, Leszek Drabik2,3
1Department of Cardiac and Vascular Diseases, John Paul II Hospital, Jagiellonian University Medical College, Krakow, Poland. wplazak@szpitaljp2.krakow.pl.
Insights
Systemic lupus erythematosus and COVID-19 share similar pathways, including endothelial dysfunction, increasing risks for atherosclerosis and thrombosis. Understanding these links aids in managing cardiovascular complications in both conditions.
Area of Science:
- Cardiovascular Medicine
- Rheumatology
- Infectious Diseases
Background:
- Connective tissue diseases, like systemic lupus erythematosus (SLE), are linked to increased atherosclerotic and thrombotic risks due to endothelial dysfunction.
- COVID-19 infection presents with hypercoagulable and hyperinflammatory states, sharing pathogenic mechanisms with rheumatic diseases.
Purpose of the Study:
- To explore the shared pathophysiological mechanisms between SLE and COVID-19, focusing on endothelial dysfunction.
- To discuss the implications for atherosclerosis and thrombosis in both conditions.
- To highlight therapeutic strategies for improving endothelial function.
Main Methods:
- Review of existing literature on SLE, COVID-19, endothelial dysfunction, atherosclerosis, and thrombosis.
- Comparative analysis of pathogenic mechanisms in SLE and COVID-19.
- Discussion of therapeutic interventions for endothelial dysfunction.
Main Results:
- SLE and COVID-19 exhibit similar pathologies, including endothelial activation/dysfunction, complement system activation, antiphospholipid antibodies, and neutrophil extracellular traps.
- Autoimmunity in both diseases contributes to hyperinflammation, hypercoagulability, hypofibrinolysis, and thromboembolic events.
- Cardiovascular manifestations like coronary artery disease, stroke, and pulmonary embolism are associated with these shared mechanisms.
Conclusions:
- Endothelial dysfunction is a central mechanism linking SLE and COVID-19, driving atherosclerosis and thrombosis.
- Recognizing these pathophysiological similarities is crucial for managing cardiovascular risks in patients with SLE and post-COVID-19.
- Targeting endothelial dysfunction may offer therapeutic benefits for preventing thromboembolic complications in both diseases.
Abstract:
An increased risk of atherosclerotic and thrombotic complications characterizes connective tissue diseases. Endothelial dysfunction is the basis for the initiation and progression of atherosclerosis and thrombosis. We present systemic lupus erythematosus (SLE) as a model rheumatic disease with endothelial dysfunction and discuss its mechanisms, factors that influence the early onset and rapid progression of atherosclerosis, and the increased risk of thromboembolic events. We focus on established methods to improve endothelium function, including statins, antiplatelet, and antithrombotic therapy. Hypercoagulable and hypofibrinolitic states and a hyperinflammatory response characterize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Several pathogenic mechanisms are typical for an acute phase of Covid-19 post-Covid syndrome and connective tissue diseases: endothelial dysfunction, elevated antiphospholipid antibody titer, activation of the complement system, and formation of extracellular neutrophil traps (NET). The current review discusses the mechanisms underlying SLE and the COVID-19 in the context of endothelial function, atherosclerosis, and thrombosis (Graphical abstract). Key Points • The pathophysiology of systemic lupus erythematosus (SLE) and Covid-19 shows some similarities, such as endothelial cell activation and dysfunction, the activation of complementary systems, the presence of antiphospholipid antibodies, and the formation of extracellular neutrophil traps. • Autoimmunity in both diseases creates the basis for hyperinflammatory, hypercoagulable, and hypofibrinolitic states and their thromboembolic complications. • This paper presents our perspective on the mechanisms behind the cardiovascular manifestations of SLE and COVID-19, with a particular emphasis on endothelial dysfunction. Covid-19 and systemic lupus erythematosus-potential similarities in pathophysiology. Figures of the panel illustrate the clinical manifestations of endothelial dysfunction, atherosclerosis, and thromboembolism, including coronary artery disease ([A] coronary angiography with left anterior descending artery stenosis and [B] scintigraphy with reduced perfusion in the myocardial apical segments), stroke ([C] carotid angiography, left carotid artery occlusion) and pulmonary embolism ([D]computed tomography with thrombus in the right pulmonary artery).
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Endocarditis II: Clinical Features of Infective Endocarditis
Coronary Artery Disease II: Pathophysiology
Atherosclerosis I: Introduction
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Rheumatic Heart Disease I: Introduction

